An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)

The primary objective of this study is to evaluate the effect of immunosuppressive therapy (IST) in participants treated with asfotase alfa who demonstrate immune-mediated loss of effectiveness (LoE).

Start Date01 Oct 2024

Sponsor / Collaborator

Alexion Pharmaceuticals, Inc.

CTRI/2024/08/072110 / Not yet recruitingNot ApplicableIIT

Evaluation of role of Vitamin B12 and folate in Open Angle Glaucoma - nil

Start Date30 Aug 2024

Sponsor / Collaborator-

IRCT20240722062513N1 / SuspendedPhase 2IIT

Investigating the effect of the active form of folate compared to folic acid on homocysteine level inpostmenopausal women with metabolic syndrome

Start Date29 Aug 2024

Sponsor / Collaborator

Tehran University of Medical Sciences

100 Clinical Results associated with Folic Acid

100 Translational Medicine associated with Folic Acid

100 Patents (Medical) associated with Folic Acid

35,412

Literatures (Medical) associated with Folic Acid

01 Oct 2108·Psychiatria DanubinaQ4 · MEDICINE

HOMOCYSTEINE, PYRIDOXINE, FOLATE AND VITAMIN B12 LEVELS IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER

Q4 · MEDICINE

Article

Author: Ergül Belge Kurutaş ; Nilfer Şahin ; Olcay Güngör ; Hatice Altun

BACKGROUND:

In our study, we aimed to evaluate the serum homocysteine levels, pyridoxine, folate and vitamin B12 levels in children with attention deficit hyperactivity disorders (ADHD).

SUBJECTS AND METHODS:

This study included 30 newly diagnosed drug-naive children with ADHD (23 males and 7 female, mean age 9.3±1.8 years) and 30 sex-and age matched healthy controls. The diagnosis of ADHD was made according to DSM-V criteria. Children and adolescents were administered the Schedule for Affective Disorders and Schizophrenia for School Aged Children, Present and Lifetime Version, the Conners' Parent Rating Scale-Revised, Long Form, the Conners' Teacher Rating Scale and the Wechsler Intelligence Scale for Children Revised (WISC-R) for all participants. Homocysteine, pyridoxine, folate and vitamin B12 levels were measured with enzyme-linked immunosorbent assay.

RESULTS:

Homocysteine, pyridoxine, folate and vitamin B12 levels were significantly lower in children with ADHD compared with their controls (p<0.05). A positive significant correlation was observed between the all WISC-R scores and vitamin B12 level in patients (r=0.408, p=0.025).

CONCLUSIONS:

The results obtained in this study showed that reduced homocysteine, pyridoxine, folate and vitamin B12 levels could be a risk factor in the etiology of ADHD.

31 Dec 2024·Journal of psychosomatic obstetrics and gynaecology

Investigating socioeconomic disparities of Kangaroo mother care on preterm infant health outcomes

Article

Author: Naz, Sidra ; Kargbo, Alpha ; Fatima, Laraib ; Ameeq, Muhammad ; Hassan, Muhammad Muneeb ; Tahir, M H

Several studies have been conducted to examine the complicated relationships between various factors that influence Kangaroo mother care (KMC) for preterm infants. However, the extended socio-economic model has not been seen in any of the previous studies that looked into the factors related to KMC and how it affects the health outcomes of babies born before in our study population. This study examines the various dimensions of KMC implementation and its influence on the health outcomes of premature infants. The current cross-sectional study was carried out in South Punjab, Pakistan, covering both private and public KMC units in obstetrics and gynecology departments. The study included a sample size of 719 patients and was conducted during a period covering 21 September 2022 to 14 October 2023. Multinomial logistic regression analysis is employed to ascertain the factors by using SPSS-26 (SPSS Inc., Chicago, IL). The use of folic acid (OR: 1.44; 95% CI: 0.87-3.11) and factor anemia (OR: 8.82; 95% CI: 1.69-14.59) no significantly correlated with better health outcomes, while environmental toxin exposure had a negative impact (OR: 0.90). The findings underscore the need for comprehensive interventions and policies to bridge socioeconomic gaps, ensuring all preterm infants benefit from KMC.

31 Dec 2024·The Journal of dermatological treatment

The wide variety of methotrexate dosing regimens for the treatment of atopic dermatitis: a systematic review

Review

Author: Gerbens, Louise A A ; El Khattabi, Hajar ; Caron, Anouk G M ; van Huizen, Astrid M ; Bloem, Manja ; Denswil, Nerissa P ; Spuls, Phyllis I ; de Waal, Ayla C

Background:Methotrexate is an off-label therapy for atopic dermatitis. A lack of consensus on dosing regimens poses a risk of underdosing and ineffective treatment or overdosing and increased risk of side effects. This systematic review summarizes the available evidence on dosing regimens.Materials and methods:A literature search was conducted, screening all randomized controlled trials (RCTs) and guidelines published up to 6 July 2023, in the MEDLINE, Embase, and Cochrane Library databases.Results:Five RCTs and 21 guidelines were included. RCTs compared methotrexate with other treatments rather than different methotrexate dosing regimens. The start and maintenance doses in RCTs varied between 7.5-15 mg/week and 14.5-25 mg/week, respectively. Despite varied dosing, all RCTs demonstrated efficacy in improving atopic dermatitis signs and symptoms. Guidelines exhibited substantial heterogeneity but predominantly proposed starting doses of 5-15 mg/week for adults and 10-15 mg/m²/week for children. Maintenance doses suggested were 7.5-25 mg/week for adults and 0.2-0.7 mg/kg/week for children. One guideline suggested a test dose and nearly half advised folic acid supplementation.Conclusion:This systematic review highlights the lack of methotrexate dosing guidelines for atopic dermatitis. It identifies commonly recommended and utilized dosing regimens, serving as a valuable resource for clinicians prescribing methotrexate off-label and providing input for an upcoming consensus study.

News (Medical) associated with Folic Acid

17 Sep 2024

·www.prnewswire.com

Gates Foundation Report Calls for Targeted Global Health Spending to Save Millions of Children from Malnutrition and Disease

New modeling shows 40 million more children will suffer from hunger's worst effects by 2050 due to climate change, but immediate action could instead boost health, spur economic growth SEATTLE, Sept. 17, 2024 /PRNewswire/ -- In its eighth annual Goalkeepers report released today, the Bill & Melinda Gates Foundation urged world leaders to increase global health spending where it is needed most in order to boost children's health and nutrition, especially in the face of the global climate crisis. The Goalkeepers report, "A Race to Nourish a Warming World," projects that without immediate global action, climate change will condemn an additional 40 million children to stunting and 28 million more to wasting between 2024 and 2050. Scaling up solutions now can avoid this outcome, while also building resilience to climate change and spurring much-needed economic growth. In 2023, the World Health Organization estimated that 148 million children experienced stunting, a condition where children don't grow to their full potential mentally or physically, and 45 million children experienced wasting, a condition where children become weak and emaciated, leaving them at much greater risk of developmental delays and death. These are the most severe and irreversible forms of chronic and acute malnutrition. At the same time, as global challenges intensify, the total share of foreign aid going to Africa has decreased. In 2010, 40% of foreign aid went to African countries. But that number is now down to just 25%—the lowest percentage in 20 years—despite more than half of all child deaths occurring in sub-Saharan Africa. This trend leaves hundreds of millions of children at serious risk of dying or suffering from preventable diseases and threatens the unprecedented progress the world made in global health across Africa between 2000 and 2020. "Today, the world is contending with more challenges than at any point in my adult life: inflation, debt, new wars. Unfortunately, aid isn't keeping pace with these needs, particularly in the places that need it the most," writes report author Bill Gates, co-chair of the Bill & Melinda Gates Foundation. "I think we can give global health a second act—even in a world where competing challenges require governments to stretch their budgets." According to Gates, malnutrition is "the world's worst child health crisis," and climate change is only making it worse. Amidst this crisis, Gates calls for maintaining global health funding; immediately addressing the growing threat of child malnutrition by supporting the Child Nutrition Fund, a new platform that coordinates donor financing for nutrition; and governments fully funding the established institutions that have proven effective at protecting millions of lives each year. These institutions include Gavi, the Vaccine Alliance, which is due to hold its next funding replenishment in 2025; and the Global Fund to Fight AIDS, Tuberculosis and Malaria, which is expected to also hold its replenishment next year. "If we do these three things, we won't just usher in a new global health boom and save millions of lives—we'll also prove that humanity can still rise to meet our greatest challenges," Gates writes. The report also shines a light on the catastrophic economic costs of malnutrition and highlights solutions that can help mitigate them. According to the World Bank, the cost of undernutrition is US$3 trillion in productivity loss every year, because malnutrition stunts people's physical and cognitive abilities. In low-income countries, that loss ranges from 3% to 16% (or more) of GDP, which amounts to a permanent 2008-level global recession every year. Proven Tools Exist Today "The best way to fight the impacts of climate change is by investing in nutrition...Malnutrition makes every forward step our species wants to take heavier and harder," Gates writes. "But the inverse is also true. If we solve malnutrition, we make it easier to solve every other problem. We solve extreme poverty. Vaccines are more effective. And deadly diseases like malaria and pneumonia become far less fatal." The report highlights proven tools that are helping solve malnutrition, building people's resilience to the worst impacts of climate change, and further driving down childhood deaths. They include: New agricultural technologies that are producing up to two to three times more milk and safer milk, which can prevent millions of cases of child stunting by 2050. Modeling shows that in India, Ethiopia, Kenya, Nigeria, and Tanzania, these technologies can prevent 109 million cases of child stunting by 2050. Efforts to scale up new ways of fortifying pantry staples, such as salt and bouillon cubes, can reduce millions of cases of anemia and prevent deaths due to neural tube defects. In Ethiopia, a new process to fortify salt with iodine and folic acid could lead to a 4% reduction in anemia and could eliminate up to 75% of all deaths and stillbirths due to neural tube defects. In Nigeria, fortifying bouillon cubes with iron, folic acid, zinc, and vitamin B12 could avert up to 16.6 million cases of anemia and up to 11,000 deaths from neural tube defects. Efforts to provide a high-quality prenatal vitamin for pregnant women could save almost half a million lives and improve birth outcomes for 25 million babies by 2040. Adopting multiple micronutrient supplements (MMS) costs as little as $2.60 for an entire pregnancy in all low- and middle-income countries. The report also highlights how promising new research into the microbiome can improve people's health. Studies indicate that better gut health can help children absorb nutrients, develop strong immune systems, and grow as they should to thrive. A deeper understanding of gut health, Gates writes, has the potential to change not just how the world treats malnutrition but also overnutrition, which impacts wealthy countries. This year's report also features essays from farmers and experts on the frontlines of the malnutrition crisis, who explain the impacts these tools are making in their communities, including Sushama Das, a dairy farmer in Astaranga, India; Coletta Kemboi, a dairy farmer in Maili Nne, Kenya; Ladidi Bako-Aiyegbusi, director of nutrition at the Nigerian Ministry of Health and Social Welfare and leader of a large-scale effort to fortify bouillon cubes; Dr. Sabin Nsanzimana, Rwandan minister of health and leader of efforts to ensure all Rwandan women have access to MMS; and Dr. Víctor Aguayo, director of child nutrition and development at UNICEF. Read their comments and the full press release here: . About the Bill & Melinda Gates Foundation Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people's health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people—especially those with the fewest resources—have access to the opportunities they need to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Mark Suzman, under the direction of Co-Chairs Bill Gates and Melinda French Gates and the board of trustees. About Goalkeepers Goalkeepers is the foundation's campaign to accelerate progress towards the Sustainable Development Goals (Global Goals). By sharing stories and data behind the Global Goals through an annual report, the Gates Foundation hopes to inspire a new generation of leaders—Goalkeepers who raise awareness of progress, hold their leaders accountable, and drive action to achieve the Global Goals. About the Global Goals On September 25, 2015, at the United Nations headquarters in New York, 193 world leaders committed to the 17 Sustainable Development Goals (Global Goals). These are a series of ambitious objectives and targets to achieve three extraordinary things by 2030: end poverty, fight inequality and injustice, and fix climate change. Media contact: [email protected] Photos from the report WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Vaccine

17 Jun 2024

·www.fiercepharma.com

India's Lupin announces CEO pick for new subsidiary as it moves into the CDMO arena

Lupin got its start back in 1968 as an Indian vitamin manufacturer, thanks to 5,000 rupees founder Desh Bandhu Gupta borrowed from his wife. From vitamin maker to pharmaceutical specialist and now contract manufacturer, India’s Lupin is embarking on a new phase of its corporate journey. Lupin on Monday unveiled its new subsidiary, Lupin Manufacturing Solutions, which is poised to work on the development, production and sale of active pharmaceutical ingredients. The company is now starting to build out its contract development and manufacturing operations business, Lupin explained in a press release. At the same time, Lupin announced Abdelaziz Toumi will take the reins as CEO of the newly formed unit. Toumi’s track record includes stints at Bayer, Merck, Catalent, Lonza and KBI Biopharma. He will be based in Switzerland and spend a considerable amount of time in India, Lupin said. “We are delighted to welcome Abdel to our team,” Lupin’s managing director, Nilesh Gupta, said in a statement. “He brings a wealth of knowledge and experience in the API CDMO space and will be instrumental in establishing LMS as a trusted and preferred partner for our global customers.” Lupin got its start back in 1968 as an Indian vitamin manufacturer, thanks to 5,000 rupees founder Desh Bandhu Gupta borrowed from his wife. The company’s first manufacturing plant churned out iron and folic acid tablets for India’s government as part of a countrywide program aimed at improving maternal and childhood health. Soon after, Lupin started producing drugs for tuberculosis, according to its website. Meanwhile, Lupin has made headlines in recent years courtesy of recalls and FDA citations. That said, the company recently cleared an FDA inspection of its plant in Nagpur, India, with zero observations. Prior to that, Lupin revealed it had signed a license and supply agreement with Thailand’s OLIC to market Fuji Pharma’s pregnancy prevention drug Nextstellis in Vietnam and the Philippines. And, last summer, Lupin became the first company to score approval in the U.S. for its generic version of Boehringer Ingelheim’s blockbuster chronic obstructive pulmonary disease treatment Spiriva HandiHaler. The approval marked the first in the U.S. for a dry powder inhaler from India, Lupin’s CEO, Vinita Gupta, said at the time. Lupin’s manufacturing footprint spans 15 facilities across India, the U.S., Brazil and Mexico, with the company claiming its “pe-eminence as a leader in formulations and APIs.” Nevertheless, the company has run into production shortfalls before. Last summer, the company recalled two batches of birth control pills on the fact that they may not have been effective at preventing pregnancy. At the time, Lupin said testing on one of the lots of Tydemy tablets found low levels of ascorbic acid and high levels of a “known impurity.” Prior to that, Lupin in Nov. of 2022 received another in a series of Form 483 citations from the FDA, with the regulatory wrist slap focusing on the company’s API plant in Manideep, India. Editor's note: This story has been updated with additional information on Lupin's manufacturing.

Drug ApprovalExecutive ChangeLicense out/in

22 May 2024

·www.sciencedaily.com

Dispelling severe 'morning sickness' myths: It's not normal or harmless, but prevention and treatment might be on the way

Late last year, geneticists made the discovery that morning sickness's most serious presentation, hyperemesis gravidarum (HG), is caused by the hormone GDF15, not human chorionic gonadotropin as previously thought. Researchers dispel common morning sickness myths and discusses potential treatments, including sensitizing people to GDF15 prior to pregnancy, similar to the way we treat allergies. Late last year, geneticist Marlena Fejzo and colleagues made the discovery that morning sickness's most serious presentation, hyperemesis gravidarum (HG), is caused by the hormone GDF15, not human chorionic gonadotropin as previously thought. In a peer-reviewed opinion article publishing May 22 in the journal Trends in Molecular Medicine, Fejzo dispels common morning sickness myths and discusses potential treatments, including sensitizing people to GDF15 prior to pregnancy, similar to the way we treat allergies. "HG can be life threatening and is associated with adverse outcomes that need to be taken seriously," says Fejzo of the Keck School of Medicine of the University of Southern California. "Now that we know that GDF15 is the most likely cause of HG, we are on the cusp of having treatments that target this hormonal pathway and end the suffering." Myth 1: Severe morning sickness is harmless and normal Pregnant people with HG are essentially starving, Fejzo says, and an increasing number of studies have demonstrated that this has serious short- and long-term clinical implications for both the parent and child. HG is a top predictor of postnatal depression, and 26% of pregnant people with HG report suicidal ideation while 18% meet the full criteria for post-traumatic stress disorder. For the child, HG is associated with preterm birth, low birth weight, and later in life, autism spectrum disorder, ADHD, depression, social problems, in addition to an increased risk of childhood cancer and respiratory and cardiovascular disease. Still, pregnant people with the condition are often dismissed by their clinicians and families. "It really is like a teratogen in pregnancy, a factor which interferes with normal fetal development, but it's still not taken seriously by a lot of medical professionals," Fejzo says. "A lot of people are brushed off and told, 'oh that's normal, it's okay, just don't take your pre-natal vitamins; you don't need them.'" At its most extreme, individuals with HG can develop Wernicke encephalopathy, a life-threatening swelling of the brain due to thymine (vitamin B1) deficiency. Since individuals with HG can have trouble even swallowing vitamins, the American College of Obstetricians and Gynecologists currently recommends that they replace broad spectrum prenatal vitamins with folic acid, but Fejzo warns that this is likely insufficient, and that thiamine supplementation is also warranted for individuals with HG. "I believe all women who have hyperemesis should be given vitamin B1 to avoid this serious brain swelling that can lead to permanent brain damage and often leads to fetal death," Fejzo says. Myth 2: Morning sickness is caused by human chorionic gonadotropic hormone (hCG) or is psychosomatic Though it was long thought that morning sickness is caused by hCG, the recent breakthrough has shown that HG's main cause is actually the hormone GDF15, which is part of a normal stress response. Usually, GDF15 is expressed only in very small amounts, but during early pregnancy it spikes by a huge amount, then wanes, and finally rises again during the third trimester. A recent Nature study co-authored by Fejzo showed that individuals who suffer from HG can have genetic variants that causes them to have lower levels of circulating GDF15 prior to pregnancy, which makes them extra sensitive when they become pregnant and are suddenly exposed to high levels. This finding has clinical implications for preventing and treating HG, since preliminary research suggests that it might be safe to manipulate GDF15 during or even prior to pregnancy. "GDF15 may be safe to manipulate in pregnancy or even prior to pregnancy," says Fejzo. "If we can increase levels of GDF15 before someone becomes pregnant, that might desensitize them, similar to how we try to desensitize people to allergens who have severe allergies," says Fejzo. "And during pregnancy, we may be able to minimize or get rid of symptoms by blocking GDF15 or its receptors in the brain stem." Myth 3: Only humans experience morning sickness Nausea and appetite loss during gestation is not a uniquely human trait -- these symptoms have been observed throughout the animal kingdom, from monkeys, dogs, and cats, to chickens, vipers, and octopuses. "I always think it's interesting that the recommendation for cats is that if they're unable to eat for a day, you should contact your veterinarian, but we don't have that recommendation out there for women with hyperemesis," says Fejzo. "If you call your doctor's office and say you haven't eaten for a day, they'll say, 'that's normal' and won't do anything. There's more proactive care for cats than humans." In addition to preventing ingestion of harmful foods, Fejzo speculates that pregnancy-induced nausea likely evolved to prevent dangerous foraging trips. "This condition likely evolved because it was probably beneficial to avoid going out searching for food during pregnancy," says Fejzo. "That may still be true for animals, but people don't need this anymore, so let's end the suffering once and for all if we can." Now, Fejzo is working toward developing and testing the proposed GDF15-based treatments. She also plans to investigate other genes and variants of GDF15 that might contribute to HG.

100 Deals associated with Folic Acid

External Link

KEGG	Wiki	ATC	Drug Bank
D00070	Folic Acid	V04CX02 B03BB01	DB00158

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anemia, Megaloblastic	CN	Tianjin Lisheng Pharmaceutical Co., Ltd.	01 Jan 1981
Folic Acid Deficiency	JP	Fuji Pharma Co., Ltd.	01 Aug 1950
Neural Tube Defects	US	Eli Lilly & Co.	02 Jun 1947

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ischemic stroke	IND Approval	CN	Beijing Silian Pharmaceutical Co., Ltd.	24 Sep 2024
Homocysteinemia	IND Approval	CN	Beijing Silian Pharmaceutical Co., Ltd.	09 Nov 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


IEC2023	Not Applicable	-	-	High-dose folic acid	bbiqfaeazt(irlqibiziu): aHR = 0.8 (95% CI, 0.63 - 1.02)	Positive	04 Sep 2023
				No high-dose folic acid
ChiCTR-SOC-17010976 (Pubmed)	Not Applicable	Congenital Abnormalities	-	Women taking recommended dosage of FA	cluxampcmw(zjsmlzpgxr) = xvntvbxagd akfefyuktv (vzswgmvuwd )	-	07 Aug 2023
				folic acid (Women without supplementation)	cluxampcmw(zjsmlzpgxr) = podtdvhdya akfefyuktv (vzswgmvuwd )
NCT04354428 (CTgov)	Phase 2/3	COVID-19	289	Ascorbic Acid+Folic Acid (Ascorbic Acid and Folic Acid)	ccocixgork(mqcwzrpeeg) = jsewepqpcr butllaigin (pgwuzjndyz, vxlnuuxnnp - jtmmmdimxp) View more	-	08 Aug 2022
				Hydroxychloroquine Sulfate+Folic Acid (Hydroxychloroquine and Folic Acid)	ccocixgork(mqcwzrpeeg) = aoudlvboxc butllaigin (pgwuzjndyz, feccuvrvuh - gxfnwokafl) View more
EULAR2022	Not Applicable	COVID-19	-	Folic acid only	-	-	01 Jun 2022
				Methotrexate and folic acid
ASN2021	Not Applicable	Fibrosis mitochondrial DNA \| cGAS \| STING	23	Folic Acid	rduvawwvsz(eeppuduwih) = ataeftparc jeyokiqnev (vnaemqpadz ) View more	Negative	27 Oct 2021
				Folic Acid	rduvawwvsz(eeppuduwih) = kgywupahmi jeyokiqnev (vnaemqpadz ) View more
NCT02930343 (CTgov)	Phase 3	Rheumatoid Arthritis	136	Hydroxychloroquine+Folic Acid+Prednisolone+Methotrexate+Leflunomide (Group 1- MTX+LEF+HCQ)	hsxjryhhrm(akklczpifp) = eavnjqzbut enysqsxcdp (grvkdfmbqy, ndiqsaawam - kouhbcgiza) View more	-	10 Jun 2021
				Hydroxychloroquine+Folic Acid+Prednisolone+Sulfasalazine+Methotrexate (Group 2- MTX+SSZ+HCQ)	hsxjryhhrm(akklczpifp) = iirmbwctue enysqsxcdp (grvkdfmbqy, dstsegwfrk - srimzbmxit) View more
NCT03172325 (CTgov)	Phase 3	Rheumatoid Arthritis	136	Adalimumab+Folic Acid+Prednisolone+Methotrexate (CinnaGen Adalimumab)	ofwfqqowvi(gsszuqnpnn) = vmkkcbozkw byvklibngh (kgickiobtd, ybvsdsnnbs - wdzxuployz) View more	-	02 Feb 2021
				Adalimumab+Folic Acid+Prednisolone+Methotrexate (AbbVie Adalimumab)	ofwfqqowvi(gsszuqnpnn) = qivewzzfxd byvklibngh (kgickiobtd, ityyumdvru - zhuupliswk) View more
NCT00655980 (VINO, CTgov)	Not Applicable	Coronary Artery Disease	687	placebo+nitrous oxide (Comparator)	qxbzsiyxie(ogctjpglym) = hymjryvigc mqdhripwcd (tumvewuttc, ojixwlrwjd - ylqytlofla) View more	-	01 Oct 2020
				standard of care (Standard of Care)	qxbzsiyxie(ogctjpglym) = pmeqsatbcg mqdhripwcd (tumvewuttc, qtacnztmgp - zsgxzbxsuw) View more
NCT00097669 (VITATOPS, CTgov)	Not Applicable	Stroke \| Ischemic Attack, Transient	8,164	Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo (Active VITATOPS Tablet (Folic Acid 2mg, B6 25mg , B12 500ug))	jbohhjczrg(wvxgccltym) = oyaniurjdn znykbbhpal (khrldirnuq, azjahdcwez - lmrrrqntal) View more	-	25 Sep 2020
				Placebo (Placebo Tablet)	jbohhjczrg(wvxgccltym) = nromshjcqy znykbbhpal (khrldirnuq, xtjigbhdfr - kojitokkum) View more
NCT01355159 (FACT, CTgov)	Phase 3	Pre-Eclampsia	2,464	Folic Acid 4 mg (Folic Acid 4 mg)	bzgzfvbybm(htorwgyxim) = kzsppzzgux zrvrvvcuki (orfxnrmryv, oxuqpfnzkk - feyqwfoixv) View more	-	07 Jul 2020
				Placebo (Placebo)	bzgzfvbybm(htorwgyxim) = xycatmxtdz zrvrvvcuki (orfxnrmryv, cdoftexhet - bipkjokntb) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis